Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Non Operating Investment Income of -$48095.0 for Q1 2026, down 232.56% year-over-year from $36281.0 in Q1 2025, and down 285.04% quarter-over-quarter from $25991.0 in Q4 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Non Operating Investment Income for 5 consecutive years, with -$48095.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 232.56% year-over-year to -$48095.0; the TTM figure through Mar 2026 stood at -$25326.0 (down 3140.34% YoY), while the FY2025 annual figure was $59050.0, up 254.89% from the prior year.
- Non Operating Investment Income fell to -$48095.0 in Q1 2026 per IKT's latest filing, from $25991.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $36281.0 in Q1 2025 and bottomed at -$167536.0 in Q2 2023.
- Historically, Non Operating Investment Income has averaged -$13858.9 across 5 years, with a median of -$234.5 in 2024.
- On a YoY basis, Non Operating Investment Income climbed as much as 1455.29% in 2025 and fell as far as 354.77% in 2025.
- Inhibikase Therapeutics' Non Operating Investment Income stood at $26828.0 in 2022, then tumbled by 94.14% to $1571.0 in 2023, then tumbled by 2582.62% to -$39002.0 in 2024, then soared by 166.64% to $25991.0 in 2025, then slumped by 285.04% to -$48095.0 in 2026.
- Business Quant data shows IKT's Non Operating Investment Income at -$48095.0 in Q1 2026, $25991.0 in Q4 2025, and -$1245.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -46,461.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -46,461.00 |
| Mar 31, 2026 | -48,095.00 |
| Dec 31, 2025 | 25,991.00 |
| Sep 30, 2025 | -1,245.00 |
| Jun 30, 2025 | -1,977.00 |
| Mar 31, 2025 | 36,281.00 |
| Dec 31, 2024 | -39,002.00 |
| Sep 30, 2024 | 2,778.00 |
| Jun 30, 2024 | 776.00 |
| Mar 31, 2024 | -2,677.00 |
| Sep 30, 2023 | 1,571.00 |
| Jun 30, 2023 | -167,536.00 |
| Sep 30, 2022 | 26,828.00 |